MX2015014939A - Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. - Google Patents
Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.Info
- Publication number
- MX2015014939A MX2015014939A MX2015014939A MX2015014939A MX2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A MX 2015014939 A MX2015014939 A MX 2015014939A
- Authority
- MX
- Mexico
- Prior art keywords
- landiolol
- hydrochloride
- period
- blood pressure
- heart rate
- Prior art date
Links
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 title abstract 4
- 229950005241 landiolol Drugs 0.000 title abstract 4
- 208000001871 Tachycardia Diseases 0.000 title abstract 3
- 238000011866 long-term treatment Methods 0.000 title 1
- 230000036772 blood pressure Effects 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010049447 Tachyarrhythmia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención proporciona un nuevo uso de clorhidrato de landiolol para la reducción persistente de la frecuencia cardíaca durante el período de administración de clorhidrato de landiolol en el tratamiento de un ser humano que sufre de taquicardia, taquiarritmia o presión sanguínea elevada, en donde el clorhidrato de landiolol se administra en una dosis constante de más de 5 µg/kg/min, específicamente de al menos 10 µg/kg/min durante un período de al menos 2 horas y en donde la frecuencia cardíaca y/o presión sanguínea de dicho paciente se reducen de modo persistente durante el período de administración en comparación con la frecuencia cardíaca y/o presión sanguínea antes del tratamiento y no se produce ningún efecto de "overshoot" después de la terminación de dicha administración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165582.1A EP2796139A1 (en) | 2013-04-26 | 2013-04-26 | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
| PCT/EP2014/058456 WO2014174076A1 (en) | 2013-04-26 | 2014-04-25 | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015014939A true MX2015014939A (es) | 2016-01-12 |
| MX379191B MX379191B (es) | 2025-03-10 |
Family
ID=48226997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014939A MX379191B (es) | 2013-04-26 | 2014-04-25 | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10722516B2 (es) |
| EP (2) | EP2796139A1 (es) |
| JP (1) | JP2016517860A (es) |
| KR (1) | KR102268161B1 (es) |
| CN (1) | CN105324118A (es) |
| AU (1) | AU2014259352B2 (es) |
| BR (1) | BR112015027051A2 (es) |
| CA (1) | CA2910066C (es) |
| CL (1) | CL2015003145A1 (es) |
| DK (1) | DK2988750T4 (es) |
| EA (1) | EA030589B1 (es) |
| ES (1) | ES2906551T3 (es) |
| FI (1) | FI2988750T4 (es) |
| HR (1) | HRP20220470T4 (es) |
| HU (1) | HUE058189T2 (es) |
| IL (1) | IL242220B (es) |
| LT (1) | LT2988750T (es) |
| MX (1) | MX379191B (es) |
| NZ (1) | NZ713295A (es) |
| PH (1) | PH12015502465A1 (es) |
| PL (1) | PL2988750T5 (es) |
| PT (1) | PT2988750T (es) |
| SG (1) | SG11201508824RA (es) |
| SI (1) | SI2988750T2 (es) |
| TN (1) | TN2015000480A1 (es) |
| UA (1) | UA117243C2 (es) |
| WO (1) | WO2014174076A1 (es) |
| ZA (1) | ZA201508050B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2796139A1 (en) | 2013-04-26 | 2014-10-29 | AOP Orphan Pharmaceuticals AG | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CN114031601B (zh) * | 2022-01-12 | 2022-03-18 | 南京桦冠生物技术有限公司 | 一种盐酸兰地洛尔的制备方法 |
| WO2025024637A1 (en) * | 2023-07-25 | 2025-01-30 | Atai Therapeutics, Inc. | Compositions for limiting sympathomimetic effects of psychedelic therapeutics |
| CN118975994B (zh) * | 2024-08-26 | 2025-10-28 | 北京阳光诺和药物研究股份有限公司 | 一种注射用β-阻滞剂的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004323370A (ja) | 2003-04-22 | 2004-11-18 | Ono Pharmaceut Co Ltd | 麻酔薬と塩酸ランジオロールとを組み合わせてなる併用剤 |
| JP4816083B2 (ja) | 2003-08-08 | 2011-11-16 | 小野薬品工業株式会社 | 短時間型β遮断薬を有効成分とする心拍数減少剤 |
| JP4784037B2 (ja) | 2003-08-27 | 2011-09-28 | 独立行政法人国立がん研究センター | 塩酸ランジオロールを含有する頻脈性不整脈の治療剤 |
| CN1827109A (zh) | 2006-04-14 | 2006-09-06 | 北京润德康医药技术有限公司 | 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺 |
| US20100311738A1 (en) | 2007-12-21 | 2010-12-09 | Aop Orphan Pharmaceuticals Ag | Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists |
| CN101732319B (zh) | 2008-11-26 | 2012-11-07 | 天津市汉康医药生物技术有限公司 | 含有盐酸兰地洛尔活性成分的注射用药物组合物及其制备方法 |
| CN102232930B (zh) | 2010-05-06 | 2013-03-27 | 南京海辰药业有限公司 | 盐酸兰地洛尔药物组合物及其制备方法 |
| JP2010248263A (ja) | 2010-08-04 | 2010-11-04 | National Cancer Center | 塩酸ランジオロールを含有する頻脈性不整脈の治療剤 |
| CN102475706A (zh) | 2010-11-28 | 2012-05-30 | 天津市汉康医药生物技术有限公司 | 一种供注射用盐酸兰地洛尔药物组合物及其制备方法 |
| EP2796139A1 (en) | 2013-04-26 | 2014-10-29 | AOP Orphan Pharmaceuticals AG | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
-
2013
- 2013-04-26 EP EP13165582.1A patent/EP2796139A1/en not_active Withdrawn
-
2014
- 2014-04-25 KR KR1020157031952A patent/KR102268161B1/ko active Active
- 2014-04-25 CN CN201480033912.7A patent/CN105324118A/zh active Pending
- 2014-04-25 HU HUE14720107A patent/HUE058189T2/hu unknown
- 2014-04-25 HR HRP20220470TT patent/HRP20220470T4/hr unknown
- 2014-04-25 WO PCT/EP2014/058456 patent/WO2014174076A1/en not_active Ceased
- 2014-04-25 SI SI201431953T patent/SI2988750T2/sl unknown
- 2014-04-25 EA EA201592058A patent/EA030589B1/ru not_active IP Right Cessation
- 2014-04-25 NZ NZ713295A patent/NZ713295A/en unknown
- 2014-04-25 US US14/787,217 patent/US10722516B2/en active Active
- 2014-04-25 AU AU2014259352A patent/AU2014259352B2/en active Active
- 2014-04-25 LT LTEPPCT/EP2014/058456T patent/LT2988750T/lt unknown
- 2014-04-25 BR BR112015027051A patent/BR112015027051A2/pt not_active Application Discontinuation
- 2014-04-25 PL PL14720107.3T patent/PL2988750T5/pl unknown
- 2014-04-25 JP JP2016509488A patent/JP2016517860A/ja active Pending
- 2014-04-25 SG SG11201508824RA patent/SG11201508824RA/en unknown
- 2014-04-25 MX MX2015014939A patent/MX379191B/es unknown
- 2014-04-25 PT PT147201073T patent/PT2988750T/pt unknown
- 2014-04-25 ES ES14720107T patent/ES2906551T3/es active Active
- 2014-04-25 DK DK14720107.3T patent/DK2988750T4/da active
- 2014-04-25 UA UAA201511610A patent/UA117243C2/uk unknown
- 2014-04-25 TN TN2015000480A patent/TN2015000480A1/en unknown
- 2014-04-25 EP EP14720107.3A patent/EP2988750B9/en active Active
- 2014-04-25 FI FIEP14720107.3T patent/FI2988750T4/fi active
- 2014-04-25 CA CA2910066A patent/CA2910066C/en active Active
-
2015
- 2015-10-22 IL IL242220A patent/IL242220B/en active IP Right Grant
- 2015-10-26 PH PH12015502465A patent/PH12015502465A1/en unknown
- 2015-10-26 CL CL2015003145A patent/CL2015003145A1/es unknown
- 2015-10-29 ZA ZA2015/08050A patent/ZA201508050B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| EA033298B1 (ru) | Комбинированная лекарственная форма тезофензина и метопролола | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| JP2017501154A5 (es) | ||
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MY204827A (en) | Semaglutide in medical therapy | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| RU2014150946A (ru) | Способ снижения веса |